Metastatic lung cancers, advanced digestive tract cancers, advanced head and neck cancer, and other advanced malignant tumors
Conditions
Interventions
Sponsors
Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged >= 18 years. 2. Patients with advanced cancer who have been confirmed by histology or cytology and who have received immunotherapy (not limited to cancer types). 3. Subjects must have measurable lesions by CT or MRI according to RECIST 1.1 criteria. 4. Patients who have previously failed standard treatment and/or cannot tolerate standard treatment and are planning to receive immunotherapy. 5. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up.
Exclusion criteria
Exclusion criteria: 1. The expected survival time is less than 3 months. 2. Received anti-tumor vaccine or other anti-tumor drugs with immunostimulatory effect. 3. Received anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody or anti-CTLA-4 antibody treatment (including ipilimumab or any specific action on T cell costimulation or checkpoint pathway) other antibodies or drugs). 4. The patient is undergoing other trials against concomitant drug treatment, and the drug cannot be discontinued during the study. 5. The investigator believes that the patient's medical history or concurrent conditions may affect the patient's ability to comply with the trial. 6. Other conditions deemed inappropriate by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DNA methylation;Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sum of longest diameters of target lesions;Overall survival; | — |
Countries
China
Contacts
Public ContactZhang Yanjie
Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed